Skip to main content

Table 4 WST-1 proliferation assay for BT474 cells treated with atRA, trastuzumab, and tamoxifen

From: Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations

  Fraction affected  
Dose atRA Trastuzumab Tamoxifen atRA + Tzmab + Tam Combination index
0.2 0.20 ± 0.028 0.24 ± 0.017 0.10 ± 0.063 0.58 ± 0.017 0.15 ± 0.014
0.4 0.29 ± 0.041 0.48 ± 0.032 0.15 ± 0.036 0.84 ± 0.007 0.01 ± 0.001
0.6 0.37 ± 0.023 0.58 ± 0.012 0.25 ± 0.087 0.89 ± 0.010 0.01 ± 0.001
1 0.46 ± 0.046 0.63 ± 0.023 0.29 ± 0.055 0.90 ± 0.006 0.01 ± 0.003
5 0.55 ± 0.038 0.65 ± 0.015 0.37 ± 0.055 0.89 ± 0.009 0.06 ± 0.011
10 0.57 ± 0.041 0.66 ± 0.030 0.59 ± 0.048 0.90 ± 0.003 0.09 ± 0.020
  1. Doses of all-trans retinoic acid (atRA), trastuzumab (Tzmab), and tamoxifen (Tam) in μM, μg/ml, and μM, respectively. Each value is the mean of three independent experiments (with eight replicate wells for each treatment) ± standard error.